April 19, 2015Open Access

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab. (Funded by Merck; KEYNOTE-001 ClinicalTrials.gov number, NCT01295827.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Garon et al. (Sun,) studied this question.

www.synapsesocial.com/papers/69d7218aef370a38abf50ccd — DOI: https://doi.org/10.1056/nejmoa1501824

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Hallmarks of Cancer: The Next Generation· 2011 · 66,133 citations
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion· 1999 · 2,475 citations
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers· 2015 · 459 citations
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Authors

Edward B. Garon

Naiyer A. Rizvi

Rina Hui

Journals

New England Journal of Medicine

Actions

Institutions

Cornell University

University of Pennsylvania

Columbia University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion